[ad_1]
New Delhi:
The Phase 1 human medical trials of two COVID-19 vaccine candidates developed indigenously by Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been accomplished and the trials have moved to Phase 2, ICMR Director General Balram Bhargava stated on Tuesday.
Addressing a press briefing, he stated as soon as a protected and efficient vaccine is developed, the main target needs to be on prioritisation and its truthful distribution, roll-out and chilly chain logistics, stockpiling and coaching of people that could be administering the vaccine.
There are about 141 candidates which might be being studied world over and 26 are in several phases of medical trials, he stated.
“At the present moment, there are three vaccines which are in different phases of clinical testing in India. The first one is the inactivated virus vaccine developed by Bharat Biotech which has completed its Phase 1 study in 11 sites and has started its Phase 2 study. Phase 1 and 2 are safety and very early efficacy studies.”
“Similarly Zydus Cadila’s DNA vaccine has also completed Phase 1 studies in 11 sites and started its Phase 2 trials which is also progressing. Recombinant Oxford vaccine to be manufactured by Serum Institute of India, Pune was given approval yesterday for Phase 2 and 3 clinical trials which would start within a week at 17 sites,” Mr Bhargava stated on the briefing.
Underlining the urgency for the necessity of a vaccine, the ICMR official stated although the pandemic is progressing quickly, growing a vaccine takes time “not only from the science aspect, but also from the social, cultural and regulatory aspects”.
He, nonetheless, emphasised that until a protected and efficient vaccine turns into obtainable, sustained behavioural change, bodily distancing, carrying masks and correct hand hygiene, might be the most effective vaccine obtainable in the intervening time, and even these measures must be continued completely.
[ad_2]
Source hyperlink